BUSINESS● LOWSep 8 · Sep 8, 2026, 5:54 PM
Beam drops after updating Phase 1/2 trial data for gene-editing drug
Seeking Alpha Tech · global
Beam's stock dropped after the company updated Phase 1/2 trial data for its gene-editing drug, reflecting investor reaction to the latest clinical information. This is significant for the company's valuation and pharmaceutical development.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS36m agoPAMA backs FG’s commitment to affordable long-term industrial financingVanguard NigeriaBUSINESS39m agoApple earnings beat expectations, but rising chip costs worry investorsEuroNews [en]